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Association of response endpoints with survival outcomes
in multiple myeloma
S Lonial
1 and KC Anderson
2
Since the introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs (IMiDs) thalidomide and
lenalidomide, more patients with multiple myeloma are achieving deep, durable responses and disease control, and are living
longer. These improvements have afforded more robust analyses of the relationship between response and survival. Generally,
these studies have demonstrated that improvements in the quality of response across all stages of treatment are associated
with better disease control and longer survival. Thus, achievement of maximal response should be strongly considered, particularly
in the frontline setting, but must also be balanced with tolerability, quality of life and patient preferences. In select patients,
achievement of a lesser response may be adequate to prolong survival, and attempts to treat these patients to a deeper response
may place them at unnecessary risk without signiﬁcant beneﬁt. Maintenance therapy has been shown to improve the quality
of response and disease control and, in some studies, survival. Studies support maintenance therapy for high-risk patients as a
standard of care, and there are emerging data supporting maintenance therapy in standard-risk patients to improve progression-
free and possibly overall survival. Multidrug regimens combining a proteasome inhibitor and an IMiD have shown exceptional
response outcomes with acceptable increases in toxicity in both the frontline and salvage settings, and are becoming a standard
treatment approach. Moving forward, the use of immunophenotypic and molecular response criteria will be essential in better
understanding the impact of highly active and continuous treatment regimens across myeloma patient populations. Future
translational studies will help to develop antimyeloma agents to their fullest potential. The introduction of novel targeted therapies,
including the IMiD pomalidomide and the proteasome inhibitors carﬁlzomib and ixazomib (MLN9708), will provide greater options
to individualize treatment and help patients achieve a clinically meaningful response.
Leukemia (2014) 28, 258–268; doi:10.1038/leu.2013.220
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INTRODUCTION
Over the past decade, the introduction of targeted therapy with
the proteasome inhibitor (PI) bortezomib (approved by the US
Food and Drug Association in 2003) and immunomodulatory
drugs (IMiDs) lenalidomide and thalidomide (both approved in
2006) have vastly improved the outcomes for patients with
multiple myeloma (MM).
1–3 When used alone or as part of
combination regimens, these therapies have been shown to
provide deep and durable, quality responses, which have
translated into advances in disease control and survival. During
the early years of their use from 2003 to 2006, the 5-year survival
estimate in MM increased to 40.3% compared with 32.8%
between 1998 and 2002.
2 Unfortunately, most patients still face
the challenges of disease progression and eventually succumb to
the disease.
The treatment paradigm for MM is evolving, but the general
goals continue to include rapid disease control to reverse
complications, extending disease control and survival, and
maintaining quality of life.
4–6 In recent years, a growing body of
evidence indicates a relationship between the quality of response
to treatment (depth and durability) and clinical outcomes. Before
the introduction of targeted therapies, most patients were unable
to achieve quality responses without undergoing high-dose
therapy with autologous stem cell transplant (HD-ASCT). Given
that HD-ASCT was initially limited to patients under 65 years of
age and MM has a median onset of 70 years,
5 many patients were
ineligible for transplantation and instead received a less-intensive
treatment. As a consequence, achievement of a deep and durable
response was rare and thus, it was challenging to relate response
and survival.
7–10 Furthermore, these studies generally excluded
high-risk patients for whom the beneﬁt of achieving and
maintaining a complete response (CR) is more evident.
11
The rapid adoption of targeted therapies has afforded a greater
focus on depth and duration of response and their impact on
outcomes.
12–17 Both transplant-eligible and -ineligible patients
now achieve quality responses, including CRs, across all phases of
treatment (induction, consolidation, maintenance and salvage).
18
The development of triplet combinations that combine a PI with
an IMiD and a corticosteroid or chemotherapy has provided
unprecedented levels of response in the frontline and relapsed
settings in high-risk patients.
19–25 Generally, studies with targeted
therapies support an aggressive treatment paradigm to maximize
the quality of response and minimize the burden of the malignant
clone, particularly in the early treatment phase.
26–32 Even at the
time of presentation multiple clones can be present. Theoretically,
an aggressive upfront treatment strategy may improve the depth
and durability of response and inhibit clonal evolution, but clinical
studies are needed to support this premise.
33–35
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6,36,37 Quality of
response alone is not a validated surrogate marker of overall
survival (OS).
38 There are currently no deﬁnitive data to validate the
association between quality of response and survival outcomes.
Moreover, the association of depth of response with outcomes is
not universal across studies. Biologically, MM is a spectrum of
diseases and its course and response to therapy can be highly
variable. Some patients achieve very good initial responses that are
short-lived, whereas others achieve only minimal responses
(MRs) that are durable and clinically relevant.
39–41 Furthermore,
aggressive treatment can be associated with greater toxicity than
conventional approaches, and thus, the risk-to-beneﬁt must be
compared with alternative approaches that favor ‘disease control’
with less-intensive sequential regimens.
6,37 Both strategies have
merit but in the context of speciﬁc patient populations and
disease characteristics. Risk-adapted strategies favor aggressive
treatment in high-risk patients and more conventional
approaches in standard-risk patients.
5 However, risk stratiﬁcation is
not sufﬁciently accurate to predict the quality of a treatment
response for individual patients. Undertreatment could result in
failure to achieve a potential cure in standard-risk patients or rapid
loss of disease control in high-risk patients. For these reasons, it may
be preferable to maximize the response of all patients at diagnosis
and use personalized treatment in the consolidation and
maintenance phases.
In view of the evolving treatment strategies in MM, it is
important to consider the impact depth of response has on clinical
outcomes collectively and within the various treatment phases
and disease settings. Although current data do not address all
gaps in our knowledge, they do help to better inform treatment
decisions. Here, we provide an overview of studies that have
explored the impact of quality of response on outcomes by
transplant status and stage of treatment, and consider our
knowledge gaps. We review recent studies of triplet combinations
and highlight the need for more sensitive response criteria that
will better inform short- and long-term treatment decisions.
DEPTH OF RESPONSE AND CLINICAL OUTCOMES
A number of caveats to the data reviewed here should be
acknowledged upfront. It is important to keep in mind that
before 1998 multiple response criteria were in use with variable
deﬁnitions for CR or no deﬁnition at all.
9,10,42,43 In 1998, the
European Group for Bone Marrow and Blood Transplantation
developed the ﬁrst uniform response criteria for MM based
on: monoclonal paraprotein serum and urine levels with
electrophoresis and immunoﬁxation; the proportion of plasma
cells in the bone marrow aspirates/biopsies with histologic and
cytologic studies; bone lesions and soft tissue plasmacytomas,
with radiographic imaging and clinical evaluations.
44 Response
categories included CR, partial response (PR), MR, stable disease
and progressive disease. Then, in 2006, the International Myeloma
Working Group developed response criteria similar to that of
European Group for Bone Marrow and Blood Transplantation but
with some differences, including the addition of stringent CR and
very good partial response (VGPR) response categories.
45 Studies
also sometimes use near CR (nCR) as an additional response
category.
46
We also acknowledge that many of the studies discussed here
are retrospective, observational or exploratory analyses with
limited number of patients. Patient populations and treatments
were more homogeneous and well controlled in some studies
than in others. Also, survival data may be confounded by
the impact of subsequent or salvage therapies at the time of
progression,
1,3,47–49 which may vary based on the depth and
duration of the initial response and access to treatments. Analysis
of outcomes by the level of response may introduce selection bias,
with standard-risk patients being more likely to achieve a quality
response than high-risk patients. It is not surprising that studies
have reported no association between depth of response and
outcomes, but generally these studies were conducted before the
advent of the targeted therapy era.
9,42,50–53
In the targeted therapy era, more patients across the myeloma
spectrum are achieving quality responses with improved survival
outcomes. In a meta-analysis of phase 3 bortezomib trials that
included 2086 transplant-eligible patients,
54 the use of bortezomib
during induction signiﬁcantly improved overall response rate
(ORR), XVGPR and CR compared with non-bortezomib regimens,
which corresponded to improvements in progression-free survival
(PFS) and OS. Despite the lack of deﬁnitive data, the body of
evidence linking quality of response to outcomes is growing and
has become more compelling.
Newly diagnosed MM
Several studies have assessed the impact of response levels on
outcomes in patients with newly diagnosed MM (NDMM)
receiving HD-ASCT (Table 1). In general, studies show
that a quality response at each treatment stage—induction,
HD-ASCT, and consolidation—is associated with improved
outcomes.
19,26,55,56 Lahuerta et al.
26 evaluated response in
632 patients with NDMM treated with the GEM2000 protocol,
which used a chemotherapy induction regimen followed by
HD-ASCT. Post transplantation, there was a signiﬁcant association
between response level and outcomes with a 5-year OS rate of
74% in patients achieving a CR compared with 63% for nCR
(P¼0.01), 50% for PR (Po0.0001) and 57% for stable disease
(P¼0.01). Post induction, there were trends of improved survival
by level of response, but the association was less robust. There
was no difference in OS for achievement of CR post induction
versus post transplantation. Outcomes were worse for patients
with persistent nCR (before and after transplantation) compared
with patients whose response improved to nCR post
transplantation with a 5-year OS rate of 45% versus 72%
(P¼0.001). In a separate phase 3 IFM 2005-01 study, which
randomized 482 patients to induction with bortezomib and
dexamethasone or vincristine, doxorubicin and dexamethasone
(VAD), PFS was signiﬁcantly longer for patients achieving a VGPR
post induction compared with post transplantation (median 41.2
versus 31.1 months; P¼0.01).
27 In multivariate analysis, a response
pVGPR overall and post induction were both retained as negative
prognostic factors. Taken together, data from these and other
studies
26,27,55,56 suggest that it is important to attain a quality
response early with induction therapy and drive the response
further in the subsequent treatment stages.
Studies have also demonstrated the prognostic implications of
response durability.
51,57 Barlogie et al.
57 conducted a retrospective
analysis of OS by response at a 36-month landmark in patients
enrolled in a total therapy (TT)2 study (double HD-ASCT supported
by induction, consolidation and maintenance with thalidomide;
n¼668). Response categories included CR sustained for X36
months (n¼256), CR lost before 36 months (n¼39) and non-CR
(n¼211). Median OS was signiﬁcantly longer in the sustained
CR group (not reached) versus the non-CR group (5.6 years,
Po0.0001) and the lost-CR group (1.6 years, Po0.0001), as well as
for the comparison of non-CR to lost-CR (Po0.0001). These
survival trends were also observed in patients enrolled in a TT1
study as well as a cohort receiving other transplant protocols.
Similarly, a pooled analysis of GEM2000 and GEM2005 studies
showed that median survival was signiﬁcantly shorter for patients
with unsustained CR at 100 days (n¼29) compared with those
with a lesser response sustained for at least 100 days (n¼667),
and those with a sustained CR (n¼241)—39 months, 76 months
and not reached, respectively (Po0.001).
41
As mentioned earlier, a number of caveats of these studies
should be considered. Survival outcomes can be confounded by
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salvage therapies with targeted therapies. In the IFM 2005-01
study, patients who achieved at least a PR could enroll onto the
IFM 2005-02 study of maintenance therapy with lenalidomide.
27
Also, the relationship between quality of response and outcomes
may be confounded by tumor biology.
53 In the pooled analysis of
GEM2000 and GEM2005 studies, high-risk cytogenetics was an
independent predictor of unsustained CR.
41 On the other hand,
subgroup analyses of the IFM 2005-01 study demonstrated that a
quality response improved outcomes in high-risk patients. The
median PFS was signiﬁcantly longer in patients with International
Staging System (ISS) 2/3 disease who achieved a post-induction
VGPR versus those who did not (not reached versus 23 months;
Po0.0001), as well as in patients with high-risk cytogenetics (37
versus 24 months, respectively, P¼0.0036).
Without a trial speciﬁcally designed to assess the quality of
response, tumor biology remains a confounding factor. However,
more patients, including patients with high-risk MM, are achieving
quality responses with targeted therapy regimens compared with
conventional chemotherapy, and there is compelling evidence
that achieving a quality response can at least partially overcome
the impact of negative prognostic factors, including cytogenetic
abnormalities. This is particularly evident in the more recent non-
transplant studies where HD-ASCT is not an option, and aggressive
treatment with targeted therapies has been shown to improve
the quality of response and outcomes in high-risk patients.
These studies have generally demonstrated important associa-
tions between the quality of response and outcomes
(Table 2),
9,31,43,58–63 and pooled analyses have allowed for more
robust subgroup analyses to better examine the potential impact
of selection bias.
30,31
Gay et al.
31 conducted a pooled analysis of three phase 3 studies
that treated 1175 patients with MP with or without thalidomide
(GISMM-2001
17 and HOVON 49
64 studies) and/or bortezomib
(GIMEMA-MM-03-05
65). The highest CR rate was observed in
patients receiving VMPT plus VT maintenance (49%) with the
lowest rate in patients receiving MP (5%), with a robust association
between depth of response and outcomes. The 3-year OS rate was
91% for CR compared with 70% for VGPR (Po0.001), and 67% for PR
(Po0.001). These relationships were maintained in subgroups older
and younger than 75 years of age, and after adjustment for other
prognostic factors with multivariate analysis. The time to achieve a
CR did not have a signiﬁcant impact on the outcomes.
More recently, Gay et al.
30 conducted a separate pooled analysis
of 771 patients enrolled in the GIMEMA-MM-03-05
65 and
GEM05MAS65
21 studies, which assessed the combinations of
bortezomib with an IMiD for induction and the use of bortezomib
regimens for maintenance therapy. In response-evaluable patients
(n¼751), 36% achieved a CR, 19% a VGPR and 32% a PR. Baseline
age, ISS stage and cytogenetics—t(4;14), t(14;16) and del17p—
were similar across these response subgroups. In a landmark
analysis using a 12-month time point, the OS rate at 3 years was
75% overall and 94% in the CR subgroup versus 86% in the VGPR
subgroup (hazard ratio (HR) 0.30, 95% conﬁdence interval (CI)
0.16–0.52, Po0.001). The 3-year OS rate was superior for standard-
risk versus high-risk cytogenetics overall (76 versus 65%; HR 0.65,
95% CI 0.47–0.91, P¼0.01), but in patients with a CR, the rates
did not differ (94% versus 90%, respectively; HR 0.66, 95% CI
Table 2. Prognostic impact of response level in patients with newly diagnosed multiple myeloma: non-transplant studies
Reference
Response criteria
Study type
Treatment Response n PFS/TTP/EFS (median, mo
a/rate, %) OS (median, mo
a/rate, %)
mOS P-value
Kyle et al.
43
ECOG
Ph 3 post hoc
VBMCP±IFN or
HD-Cyc
CR
PR
85
335
— — — 61.2
b,
39.6
b
— o0.0001
EFS 3 yr P-value OS 3 yr P-value
Ofﬁdani et al.
59
EBMT
Ph 2
ThaDD XVGPR
oVGPR
28
22
—7 8
c,
37
c
0.021 — 84
61
0.053
EFS 1 yr
Palumbo et al.
61
EBMT
Ph 1/2
MPR CR/VGPR
PR/MR
20
33
— 100
88
0.034 — — —
mTTP mOS
Harousseau et al.
60
EBMT
Ph 3 post hoc
VMP arm only CR
PR
102
136
NR
21.7
— 0.004
d 46.2
NR
— 0.54
d
PFS 3 yr P-value 3 yr P-value
Gay et al.
31
IMWG
Pooled analysis of three
Ph 3 studies
MP, MPT, VMP or
VMPT-VT
CR
VGPR
PR
195
212
397
—6 7
27
27
o0.001 CR versus
VGPR and versus PR
—9 1
70
67
o0.001 CR versus
VGPR and versus PR
mOS
Oivanen et al.
9
CLMTF
Pooled analysis of
four prospective
studies
MP or combination
chemotherapy
Age p70 yr
CR
75% Response
PR
MR
SD
PD
Age 470 yr
CR
75% Response
PR
MR
SD
PD
21
95
101
42
16
49
8
26
37
10
6
20
—— —
63
58
59
49
57
10
44
44
40
32
22
4
—
o0.0001 for any
category versus PD
p0.003 for any
category versus PD
Abbreviations: CLMTF, Chronic Leukemia-Myeloma Task Force; EBMT, European Group for Blood and Marrow Transplantation; ECOG, Eastern Cooperative
Oncology Group; EFS, event-free survival; HD, high dose; mOS, median overall survival; MP, melphalan, prednisone; mPFS, median progression-free survival;
MPT, melphalan, prednisone, thalidomide; mTTP, median time to progression; MPR, melphalan, prednisone, and lenalidomide; NR, not reached; ThaDD,
thalidomide, dexamethasone and pegylated liposomal doxorubicin; VBMCP, vincristine, carmustine (BCNU), melphalan, cyclophosphamide and prednisone;
VGPR, very good partial response; VMP, bortezomib, melphalan, prednisone; VT, bortezomib, thalidomide; yr, years.
aConversion to months for studies
reporting other time increments.
bFrom time of response, converted from years to months.
cLandmark analysis after 4 months of treatment.
dMultivariate
analysis.
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analysis by ISS stage—signiﬁcant differences between the ISS
stages when considering all evaluable patients, but no difference
for patients with a CR. The prognostic signiﬁcance of CR versus
VGPR was maintained following multivariate analysis (HR 0.24,
95% CI 0.10–0.55, Po0.001). Thus, quality of response was a more
robust predictor of survival than cytogenetics or ISS stage.
Nonetheless, the potential confounding impact of salvage
therapies cannot be ruled out, although in maintenance therapy
trials variations in treatment after induction can be better
controlled because of long-term treatment protocols. Improvement
in OS in the context of maintenance trials represents the highest
level of evidence achievable in clinical practice.
Relapsed and/or refractory
In the relapsed or refractory setting, studies have also shown
associations between depth of response and outcomes, although
data are limited (Table 3).
32,58,66–71 In the phase 3 APEX study,
bortezomib was superior to high-dose dexamethasone for
patients with relapsed MM with respect to response results, time
to progression and OS.
14 An exploratory analysis of the
bortezomib arm (n¼315) showed no statistical difference in
median TTP among patients who achieved a CR (9.7 months)
compared with a VGPR (10.8 months) or a PR (8.5 months),
whereas CR was associated with signiﬁcant improvements in the
median treatment-free interval (24.1 months) compared with
VGPR (6.9 months, P¼0.007) and PR (6.4 months, P¼0.002).
66
This was likely due in part to the design of the study—once
patients achieved a CR, they continued treatment for only two
additional cycles. Finally, patients who achieved an MR had a
signiﬁcantly longer TTP compared with non-responders (4.9 versus
2.8 months, P¼0.016) and there was a trend of improved OS
(24.9 versus 18.7 months).
Other studies have also demonstrated the beneﬁt of achieving
an MR in the relapsed/refractory setting. A pooled analysis of
two phase 2 studies using thalidomide-containing regimens in
patients with relapsed MM showed an association between the
level of response and OS with a median OS of 470 months for
achievement of XVGPR, 35 months for PR and 11.7 months for
MR or non-response (Po0.001).
69 MR was favored over non-
response for PFS (6.1 versus 3.8 months) but not for OS (11 versus
14 months). In a phase 2 study of carﬁlzomib in patients with
relapsed and refractory MM (n¼266), median PFS was 10.6
months for patients achieving XVGPR (n¼14), 8.3 months
for PR (n¼47) and 9.6 months for MR (n¼34), whereas the
median for the response-evaluable population overall (n¼257)
was 3.7 months.
72
IMPROVING THE QUALITY OF RESPONSE AND OUTCOMES
Despite positive trends in treatment outcomes over the past
decade, it has become apparent that treatment strategies need to
be further developed to improve the depth and durability of
response for the individual patient with MM, particularly those
with high-risk disease, where the risk of increased toxicity with
prolonged or more aggressive treatment is outweighed by the
potential survival beneﬁt.
73 Patients with high-risk cytogenetic
abnormalities generally have a shorter duration of response, PFS
and OS than standard-risk patients, but the beneﬁt of a CR can be
more pronounced.
11,74 Given that 25–30% of the NDMM patients
present with high-risk disease,
75 efforts have been made to
improve the quality of response and outcomes in these patients,
including maintenance therapy and combinations of targeted
therapies.
Maintenance therapy
A number of studies have investigated the efﬁcacy and safety of
maintenance treatment with targeted therapies.
76–82 Studies have
consistently demonstrated that thalidomide maintenance after
HD-ASCT improves the quality of response and PFS, and some
Table 3. Prognostic impact of response level in patients with relapsed or refractory multiple myeloma
Reference
Response criteria
Study type
Patients
Treatment Response n PFS/TTP/EFS (median, mo
a/rate, %) OS (median, mo
a/rate, %)
mTTP P-value mOS P-value
Niesvizky et al.
66
mEBMT
Ph 3 post hoc
Relapsed
BTZ arm CR
VGPR
PR
MR
non-response
27
31
77
21
159
9.7
10.8
8.5
4.9
2.8
—
0.016 MR versus
non-response
NR
NR
NR
24.9
18.7
——
EFS 1 yr P-value OS 1 yr P-value
Palumbo et al.
67
IMWG
Observational
Relapsed or refractory
VDþDox
or PLD
XVGPR
PR
16
27
—8 3
16
0.02 — 90
63
0.06
OS 1 yr P-value
Pineda-Roman et al.
68
Ph 1/2
Relapsed or refractory
VT±D XMR
oMR
62
20
—— — — 7 3
20
o0.0001
mPFS P-value mOS P-value
Quach et al.
69
EMBT
Pooled analysis of two Ph 2 studies
Relapsed or refractory
TþIFN or
Tþcelecoxib
XVGPR
PR
MR or non-response
MR
non-response
9
47
48
18
30
69
14
4
6.1
3.8
—
o0.001 PR versus
MR or non-response
470
35
11.7
11
14
—
o0.001 PR versus
MR or nonR
mTTP P-value mOS 2 yr P-value
Harousseau et al
32
mEBMT
Retro of two Ph 3 trial
Relapsed or refractory
RD arm CR/VGPR
PR
114
100
27.7
12.0
o0.001 NR
44.2
59.6
42.0
0.021
Abbreviations: BTZ, bortezomib; EFS, event-free survival; IFN, interferon; IMWG, International Myeloma Working Group; mEBMT, modiﬁed European Group for
Blood and Marrow Transplantation; mo, months; mOS, median overall survival; mPFS, median progression-free survival; mTTP, median time to progression;
NR, not reached; nonR, non-response; RD, lenalidomide and dexamethasone; T, thalidomide; VD, bortezomib, dexamethasone; VGPR, very good partial
response; yr, years.
aConversion to months for studies reporting other time increments.
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83 However, there is
concern about cumulative neurotoxicity with thalidomide.
Lenalidomide maintenance has been assessed in three rando-
mized controlled trials.
76–78 In one phase 3 trial, 460 patients who
had achieved at least stable disease with HD-ASCT were
randomized to maintenance with lenalidomide or placebo.
77
Lenalidomide maintenance was associated with signiﬁcantly
improved TTP compared with placebo (46 versus 27 months;
Po0.001) and OS with a 3-year rate of 88% versus 80% (P¼0.03).
This beneﬁt was notable in patients who had not achieved CR with
HD-ASCT. In patients who achieved CR with HD-ASCT, the median
TTP was not reached in the lenalidomide maintenance arm versus
36 months in the placebo arm (natural log HR 0.53, 95% CI
 0.001–1.1), with corresponding values of 43 versus 23 months
in the non-CR subgroup (natural log HR 0.86, 95% CI 0.53–1.2;
P for interaction¼0.38). Lenalidomide maintenance was also
associated with improved OS in both subgroups, and again the
beneﬁt was more pronounced in the non-CR subgroup (natural
log HR 0.53, 95% CI 0.05–1.0; P for interaction¼0.64.) than in the
CR group (natural log HR 0.25, 95% CI  0.67–1.2). Lenalidomide
maintenance was associated with increased toxicity, including
grade 3/4 hematologic events (48% versus 17%, respectively,
Po0.001) and secondary primary malignancies (8% versus 3%,
respectively; P¼0.008). In the other two studies, lenalidomide
maintenance improved PFS, particularly among transplant-eligible
patients who achieved oVGPR with HD-ASCT
78 and transplant-
ineligible patients o75 years of age.
76 There was no improvement
in OS in either of these studies, but the investigators from both
studies noted the need for longer follow-up.
Bortezomib may also be beneﬁcial as a maintenance
therapy.
80–82,84 Sonneveld et al.
81 recently reported results of a
phase 3 study in 827 patients with NDMM who were randomized
to induction with VAD or bortezomib, doxorubicin and
dexamethasone, followed by HD-ASCT and maintenance with
thalidomide for VAD and bortezomib for bortezomib, doxorubicin
and dexamethasone. The CR rate overall was 24% for the VAD arm
versus 36% for the bortezomib, doxorubicin and dexamethasone
arm (Po0.001), the rate of improved response during maintenance
treatment was 24% and 23% (P¼0.64), respectively. Median PFS
was 28 versus 35 months, respectively (P¼0.002), and median OS
had not been reached in either arm. Subgroup analysis of patients
with the 17p13 deletion showed a XnCR rate of 20% in the VAD
arm versus 52% in the bortezomib, doxorubicin and dexamethasone
arm (P¼0.008), which corresponded to median OS of 24 versus
454 months (HR 0.36, 95% CI 0.18–0.74; P¼0.003). In the subgroup
without the 17p13 deletion, there was no difference in OS (HR 0.96,
95% CI 0.69–1.34; P¼0.81).
As data for maintenance therapy accumulate, it will be
important to assess the impact quality of response has on
outcomes in different risk groups. Although there is compelling
evidence that driving response deeper with maintenance therapy
in standard-risk patients improves PFS and possibly OS,
26,55 PFS is
not a suitable surrogate for OS in this patient population.
15,78,85,86
Without prolonged follow-up and OS data, it is unclear if those
achieving CR after HD-ASCT should receive maintenance
treatment or wait until relapse. In high-risk patients where CR
has been shown to be an important predictor of outcome,
PFS is a suitable primary endpoint as it usually correlates with
OS.
11,30,87 For high-risk patients, it is not so much a question of
maintenance therapy but rather if a multidrug combination is
appropriate.
80,83,84,87
Multidrug treatment strategies—combining PIs and
immunomodulatory drugs
Pairing PIs with IMiDs or cytotoxic agents, usually in triplet
combinations with a corticosteroid, is changing the treatment
landscape in MM as factors associated with poor outcomes appear
to have far less impact.
88 The rationale for using these
combinations is supported by the preclinical data demonstrating
that IMiDs potentiate the activity of PIs and dexamethasone
89–92
and of synergistic activity between PIs and cytotoxic agents.
93–95
Many of the toxicities associated with these drug classes are
non-overlapping. So far, triplet combinations with a PI, IMiD and
corticosteroid have demonstrated exceptional responses in both
the frontline and salvage settings, and in patients with high-risk
disease (Table 4).
19–24,96–99 Generally, these combinations have
been well tolerated, as high anti-MM activity has allowed the
development of regimens with reduced doses or different dosing
schedules of the individual agents.
20,22,24,98 Nonetheless, there are
increases in some toxicities, and there may be limits to the
combinations currently available. In the phase 2 EVOLUTION
study, for example, a quadruplet combination of bortezomib,
dexamethasone, cyclophosphamide and lenalidomide was highly
active in NDMM but did not provide a clinical beneﬁt over
bortezomib-based triplet combinations and was associated with
greater toxicity.
100 Other than the pooled analysis of the GIMEMA-
MM-03-05 and GEM05MAS65 studies discussed earlier,
30 the
impact of quality of response on outcomes has not been well
studied with these combination regimens.
19,30
REDEFINING CR—IMMUNOPHENOTYPIC AND MOLECULAR
CRS
As the rates of CR and stringent CR continue to advance, it is of
interest to further stratify the CR category. Assessment of minimal
residual disease (MRD) in bone marrow plasma cells with sensitive
assays that deﬁne immunophenotypic and molecular responses is
becoming a useful measure of response with potential
prognostic implications.
21,56,101–105 Immunophenotypic response
is assessed by multiparametric ﬂow cytometry, which uses
immunoﬂuorescence with monoclonal antibodies to plasma cell
proteins (for example, CD38, CD19 and CD117) to identify,
quantify and characterize bone marrow plasma cell
composition.
101–103 Molecular response is assessed with allele-
speciﬁc oligonucleotide PCR. Tumor-speciﬁc primers are
constructed for individual patients from the rearranged variable
region of immunoglobulin heavy-chain genes through reverse
transcription of RNA (extracted from bone marrow plasma cells)
and generation of the immunoglobulin heavy-chain genes
complementary DNA.
56,106
In a prospective analysis of 295 patients with NDMM uniformly
treated with the GEM2000 protocol, the immunophenotypic
response was assessed by the multiparametric ﬂow cytometry
method (sensitivity 10
 4) at 100 days post transplantation.
103 At
day 100, 147 patients had achieved a CR, with 58% being MRD
positive and 42% MRD negative. In the MRD-positive group, the
proportion of abnormal plasma cells corresponded to depth of
response, with a mean of 0.10% for CR, 0.21% for nCR and 0.76%
for PR (P¼0.001). PFS was signiﬁcantly longer for MRD-negative
versus MRD-positive patients (median, 71 versus 37 months,
Po0.001), as was OS (5-year rate of 82 versus 60%, P¼0.002), with
the beneﬁt independent of immunoﬁxation status. For the
immunoﬁxation-negative subgroup (that is, CR), the 5-year PFS
rate was 62% in MRD-negative versus 30% in MRD-positive
patients (Po0.001) and the 5-year OS rate was 87% versus
59%, respectively (P¼0.009).
Ladetto et al.
56 assessed MRD by the nested-PCR method
(sensitivity 10
 6) in 39 patients with NDMM who achieved a
XVGPR with HD-ASCT received consolidation therapy with
bortezomib, thalidomide, dexamethasone. At study entry, 33
patients (85%) had a VGPR following HD-ASCT, 6 had a CR (15%)
with 1 (3%) a molecular CR. All patients received one course of
bortezomib, thalidomide, dexamethasone and 31 completed four
courses. After consolidation, the CR rate improved to 49% and
molecular CR improved to 18%. After a median follow-up of 42
Response and survival in multiple myeloma
S Lonial and KC Anderson
263
& 2014 Macmillan Publishers Limited Leukemia (2014) 258–268months, all patients who achieved a molecular response were
relapse-free, whereas 11 patients who were MRD-positive had
relapsed.
These new assays will be critical in determining the beneﬁt of
aggressive and prolonged therapies, and are potential surrogate
markers for OS. In 2011, the International Myeloma Working Group
updated the response criteria to include immunophenotypic CR,
deﬁned as a stringent CR with evidence of MRD-negative disease
by multiparametric ﬂow cytometry (absence of phenotypically
aberrant clonal plasma cells in X1 million analyzed cells), and
molecular CR, a CR with evidence of MRD-negative disease by the
PCR method (sensitivity 10
 5).
107 Although a number of studies
are now using MRD as a study endpoint,
21,24,100,108 these assays
are complex, not applicable to all patients and allele-speciﬁc
oligonucleotide PCR can be expensive and time consuming, so
their wider adoption may take time.
FUTURE CONSIDERATIONS
The development of targeted therapies for MM has not only
resulted in clinically signiﬁcant improvements in outcomes but
has also advanced our understanding of this complex disease.
Collectively, the results from studies of targeted therapies support
maximizing response at all treatment stages and in most patient
subgroups. However, these are not deﬁnitive data and there
remain important gaps in our knowledge. We need to more
accurately predict the individual response level that is durable and
will extend disease control and survival without signiﬁcant risk of
treatment-related morbidity. Some patients can achieve long-term
survival with a lesser response, but this may or may not require
continuous treatment, and the potential beneﬁt of treating a
patient to a deeper response with more aggressive treatment
of shorter duration should also be weighed. Treatment
decisions—initiating a new treatment or intensifying the current
treatment—need to be better informed across the levels of
reponse.
10 This will require a greater understanding of the
molecular evolution of MM over the course of the disease and
treatment, to identify and differentiate high- to low-risk subclones
and their sensitivity to the selective pressures of speciﬁc
treatments at initial diagnosis and disease progression.
33–35 This
could lead to strategies that primarily target the highly
proliferative and genetically dynamic subclones with aggressive
multi-agent treatment, and secondarily target indolent and
genetically stable subclones with more selective regimens but
this will require further study in the clinical setting. Finally, the cost
of targeted therapies—particularly, prolonged treatment (for
example, maintenance or salvage therapy)—is an important
barrier that should be acknowledged, as some healthcare systems
may not provide support for their use in certain settings without
deﬁnitive data.
In the transplant setting, the development of triplet combina-
tions pairing PIs and IMiDs has improved the depth of response
with induction therapy. Triplet combinations allow for more rapid
and high-level responses, and may overwhelm the potential
resistance through synergistic and complementary antimyeloma
activity.
88 The quality of response with some triplet combinations
has reached a level where it might be better to defer HD-ASCT
until relapse or use it strategically to improve response.
109
Table 4. Clinical studies in patients with multiple myeloma receiving combination regimens that include a proteasome inhibitor and an IMiD
Reference
Response criteria
Study type
Treatment arm n Maximal response (%) PFS/TTP (median, mo
a/rate, %) OS (median, mo
a/rate, %)
Frontline transplant eligible
CR induction Overall 3-yr PFS 3 yr
Cavo et al.
19
mEBMT
Ph 3
VTD induction/consolidation
TD induction/consolidation
241
239
19
5
Po0.0001
58
41
P¼0.0001
68
56
P¼0.0057
86
84
P¼0.3
CR induction Transplant mPFS —
Moreau et al.
20
IMWG
Ph 3
vtD induction
VD induction
13
12
P¼0.74
29
31
P¼0.77
26
30
P¼0.22
Transplant ineligible
CR induction mPFS 3-yr PFS 3 yr
Palumbo et al.
65
IMWG
Ph 3
VMPT induction -VT maint
VMP induction
254
257
38
24
Po0.001
NR
27.3
56
41
P¼0.008
89
87
P¼0.77
CR induction mPFS 3 yr
Mateos et al.
21
mEBMT
Ph 3
VTP induction-VT or VP maint
VMP induction-VT or VP maint
130
130
28
20
P¼0.2
25
34
P¼0.1
65
74
P¼0.3
Transplant eligible/ineligible
CR overall 18-mo PFS 18 mo
Richardson et al.
22
mIMWG
Ph 1/2
VRD induction-VRD maint or HD-ASCT 66 29 75 97
sCR overall 2-yr PFS
Jakubowiak et al.
24
mIMWG
Ph 1/2
CRd induction-CRd maint or HD-ASCT 53 42 92 —
CR overall
Kumar et al.
25
mIMWG
Ph 1/2
IRd-ixazomib maint 65 18 — —
Relapsed
CR overall mTTP 24 mo
Garderet et al.
23
mEBMT
Ph 3
VTD
TD
135
134
25
14
P¼0.024
19.5
13.8
P¼0.001
71
65
P¼0.093
Abbreviations: CRd, carﬁlzomib, lenalidomide, low-dose dexamethasone; HD-ASCT, high-dose therapy with autologous stem cell transplant; IRd, ixazomib
(MLN9708), lenalidomide, low-dose dexamethasone; maint, maintenance therapy; mEBMT, modiﬁed European Group for Blood and Marrow Transplantation;
mIMWG, modiﬁed International Myeloma Working Group; mo, months; mOS, median overall survival; mPFS, median progression-free survival; mTTP, median time
to progression; TD, thalidomide, dexamethasone; VGPR, very good partial response; VMP, bortezomib, melphalan, prednisone; vtD, low-dose bortezomib,
thalidomide with dexamethasone; VTD, bortezomib, thalidomide, dexamethasone; VTP, bortezomib, thalidomide, prednisone; yr, years.
aConversion to months for
studies reporting other time increments.
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(ClinicalTrials.gov NCT01191060 and NCT01208766).
Although tolerability with multidrug regimens is always a
concern, various treatment strategies (for example, attenuated
dosing
5) are available to address these in speciﬁc patients and will
help to broaden the spectrum of patients considered for
multidrug regimens. Furthermore, novel PIs (for example,
carﬁlzomib and ixazomib [MLN9708]) and IMiDs (for example,
pomalidomide) have demonstrated good clinical activity and are
well tolerated,
24,25,72,98,99,110,111 and other classes of targeted
therapy (for example, histone deacetylase inhibitors and
monoclonal antibodies) have shown encouraging activity.
112,113
With more options, treatment regimens can be better tailored to
the individual patient.
The development of laboratory and animal models of myeloma
and the bone marrow microenvironment in the 1990s proved
instrumental in rapidly bringing the targeted therapies from the
bench to the bedside and in the development of combination
regimens.
18 Moving forward, preclinical models will help us to
better understand the mechanisms underlying the quality of
responses, to develop biomarkers that predict treatment response
and outcomes, and to maximize the potential of targeted
therapies. It is equally important to continue to develop
response assays that can further differentiate the impact of
high-level response and are accessible to a range of institutions.
CONCLUSIONS
In the era of targeted therapies, quality of response is associated
with disease control and survival in patients with MM, including
patients with high-risk disease, but until clinical trials are
speciﬁcally designed to assess this relationship, it will remain only
an association. Achievement of maximal response should be
considered upfront and at all stages of treatment, bearing in mind
tolerability, quality of life and treatment barriers including cost
and the lack of deﬁnitive data. In select patients, achievement of a
lesser response may be adequate to prolong survival and attempts
to treat these patients to a better response may place them at
unnecessary risk without a signiﬁcant beneﬁt. Multidrug regimens
combining PIs with IMiDs have improved depth of response, have
acceptable tolerability and are becoming a standard treatment
approach. The development of novel targeted therapies should
further advance these goals as clinical data in conjunction with
laboratory ﬁndings should help to facilitate the use of antimye-
loma agents to their fullest potential. Treatment should be tailored
to the disease characteristics and needs and goals of the
individual patient.
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